New research indicates that individuals who stop using popular GLP-1 drugs like semaglutide or tirzepatide may regain lost weight much more quickly than those who halt conventional lifestyle plans.
Published data in a major medical journal points out that while obese individuals frequently drop substantial amounts of their body weight while undergoing treatment, the mass comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals buying such treatments must be aware of the danger of fast weight regain when the medication ends," warns expert Dr. Susan Jebb.
Such speed of regain implies a return to starting mass in about one and a half years.
Weighing Approaches
The research, which looked at dozens of trials involving thousands of participants, contrasted the results of the injectable medications with older methods.
The team emphasize that individuals who lose weight through dieting usually have a more gradual creep back—around 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Doctors suggest the way of the injections accounts for the heightened weight return.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Artificially providing GLP-1 concentrations several times higher than normal may cause the body to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' leads to hunger is uncontrolled, making binge eating a significant risk."
A Chronic Disease?
Medical guidelines recommend the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians say that, considering the high risk of relapse, the treatment might need to be life-long.
This view is supported by pharmaceutical companies, who note that the findings "emphasize the long-term character of excess weight," similar to managing conditions like diabetes.
User Experiences
Individuals who have come off the jabs describe a intense resurgence of appetite.
"It felt as if a switch that goes on and I was suddenly ravenous," described a patient.
This challenge is compounded if individuals have not established permanent lifestyle or habit changes during therapy.
Significant Adoption
Survey data suggest that a significant number of people in the UK have tried these injections in the last 12 months, with interest being substantial.
- Adoption is higher among women than men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Finally, researchers stress that while these medications are potent tools for weight loss, they are not a magic cure and long-term success relies on combined lifestyle management.
